Guru Ownership Trend
Guru Analysis for Arcutis Biotherapeutics, Inc. (ARQT)
Arcutis Biotherapeutics, Inc. (ARQT), a key player in the Healthcare sector, continues to attract institutional attention.
As of Q1 2026, a total of 3 Super Investors (Gurus) hold positions in the company, with a combined stake valued at approximately $31.29 M.
Top institutional holders include Steven Cohen and Cliff Asness.
Institutional sentiment is currently Bullish. This is evidenced by a $4.02 M net inflow during the quarter.
Recent activity highlights Renaissance Technologies (RenTech) who increased their stake by 61.0%. Conversely, Cliff Asness reduced exposure by 6.2%.
Key Holders
Top 5 by Value
Top 5 by Conviction
Recent Activity Breakdown (Q1 2026)
Guru Consensus (Q1 2026)
FAQs for Arcutis Biotherapeutics, Inc. (ARQT)
Major holders include Steven Cohen ($13.92 M), Cliff Asness ($11.03 M), Renaissance Technologies (RenTech) ($10.39 M). According to the latest reported data, 3 tracked investment managers collectively hold approximately 1.5 M shares.
According to the latest 13F reporting period, sentiment appears Bullish (Net Buying). There was a net inflow of $4.02 M, with 2 managers increasing positions and 2 managers reducing holdings.
During the most recent reporting period, 1 managers trimmed their positions, while 1 fully exited ARQT. The total reported sell value was $3.82 M.
Yes, 0 managers opened new positions in ARQT, and 2 increased their existing holdings. The total reported buy value was $7.84 M.